Anti-EGFR Therapy Mechanism and Advances in Clinical Efficacy in Breast Cancer英文文献资料.docVIP

下载本文档

2
0
约6.78万字
约 17页
2017-05-10 发布于上海
举报
版权申诉

Anti-EGFR Therapy Mechanism and Advances in Clinical Efficacy in Breast Cancer英文文献资料.doc

1、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。。
2、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
4、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
5、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
6、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
7、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

Anti-EGFR Therapy Mechanism and Advances in Clinical Efficacy in Breast Cancer英文文献资料

HindawiPublishingCorporation JournalofOncology Volume2009,ArticleID526963,16pages doi:10.1155/2009/526963 ReviewArticle Anti-EGFRTherapy:MechanismandAdvancesin ClinicalEf?cacyinBreastCancer JohnF.Flynn,ChristinaWong,andJosephM.Wu DepartmentofBiochemistryandMolecularBiology,NewYorkMedicalCollege,Valhalla,NY10595,USA CorrespondenceshouldbeaddressedtoJosephM.Wu,josephwu@ Received26November2008;Accepted11February2009 RecommendedbyDanielChua Thisreviewwillfocusonrecentadvancesintheapplicationofantiepidermalgrowthfactorreceptor(anti-EGFR)forthetreatment ofbreastcancer.ThechoiceofEGFR,amemberoftheErbBtyrosinekinasereceptorfamily,stemsfromevidencepinpointingits roleinvariousanti-EGFRtherapies.Therefore,anincreaseinourunderstandingofEGFRmechanismandsignalingmightreveal noveltargetsamenabletointerventionintheclinic.Thisknowledgebasemightalsoimproveexistingmedicaltreatmentoptions andidentifyresearchgapsinthedesignofnewtherapeuticagents.Whiletheapproveduseofdrugslikethedualkinaseinhibitor Lapatinibrepresentssigni?cantadvancesintheclinicalmanagementofbreastcancer,con?rmatorystudiesmustbeconsideredto fostertheuseofanti-EGFRtherapiesincludingsafety,pharmacokinetics,andclinicale?cacy. Copyright?2009JohnF.Flynnetal.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense, whichpermitsunrestricteduse,distribution,andreproductioninanymedium,providedtheoriginalworkisproperlycited. 1.Introduction e?cacy not only on EGFR-expressing cells, but on HER- 2-expressing and -overexpressing cells as well, suggesting thatthetreatmentoutcomemaydependontheexpression andresponsivenessoftheheterodimerizationofHER-2with EGFR.AlthoughbothEGFRandHER-2(+ve)arefavored biomarkersofe?cacyinmanyongoinganti-EGFRclinical studies,theirexpressionisnotsu?cientlyrobustasaprog- nosticatorforclinicaloutcomesandshouldnotbesingularly usedasacriterionforevaluatingtheresponsivenessofbreast cancer cases to anti-EGFR treatment regimens [1]. Tumor targets for anti-EGFR therapy include early and advan